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ABSTRACT
Background: Non-invasive test have been constructed and evaluated mainly for binary diagnoses. The 
accuracy of non-invasive tests such as aspartate aminotransferase to platelet ratio index (APRI) and transient 
elastography/FibroScan should be evaluated especially in clinical practice. The aim of the study was to evaluate 
the accuracy of detailed fibrosis classification available for APRI and FibroScan to liver biopsy in chronic 
hepatitis B patients.
Method: A cross sectional study was conducted in 51 patients with chronic hepatitis B. The patients underwent 
laboratory test, FibroScan and liver biopsy between April 2011 and July 2013 at Adam Malik Hospital, Medan. 
Liver biopsy was assessed based on the METAVIR score. Area under receiver operating characteristic curve 
(AUROC) predictive value was used to evaluate the accuracy of APRI and FibroScan. All data were analyzed 
using SPSS 20.0.
Results: APRI versus METAVIR diagnosed severe fibrosis and cirrhosis with sensitivity 40% and specificity 
83.9%, positive predictive value (PPV) 61.5%, negative predictive value (NPV) 68.4%, positive likelihood ratio 
(LR) 2.48 and negative LR 0.72 with diagnostic accuracy 66.7%. The AUROC value was 0.619 (95% CI = 
0.446 – 0.715); kappa = 0.255; p > 0.05. FibroScan versus METAVIR predictive value with sensitivity 75% and 
specificity 67.6% were PPV 60%, NPV 67.7%, positive LR 2.31 and negative LR 0.36 with diagnostic accuracy 
70.6%. The AUROC value was 0.714 (95% CI = 0.567–0.861); kappa 0.409; p < 0.05.
Conclusion: FibroScan has better accuracy than APRI for predicting severe fibrosis and cirrhosis in patients 
with chronic hepatitis B.
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ABSTRAK
Latar belakang: Pemeriksaan non-invasif berkembang dan dievaluasi dengan baik terutama untuk diagnosis 
biner. Keakuratan pemeriksaan aspartate aminotransferase to platelet ratio index (APRI) dan transient 
elastography/FibroScan perlu dilakukan khususnya dalam praktis klinis. Tujuan penelitian ini adalah untuk 
menilai keakuratan derajat fibrosis hati berdasarkan APRI dan FibroScan terhadap biopsi hati pada pasien 
dengan penyakit hepatitis B kronik.
Metode: Penelitian potong lintang dilakukan pada 51 pasien dengan penyakit hepatitis B kronik. Dilakukan 
pemeriksaan laboratorium, FibroScan dan biopsi hati pada masing-masing pasien sejak April 2011 - Juli 2013 
di Rumah Sakit Adam Malik, Medan. Seluruh data di analisa untuk menghitung nilai APRI dan FibroScan; biopsi 
hati dianalisa berdasarkan skor METAVIR. Nilai prediktif AUROC digunakan untuk menilai akurasi APRI dan 
FibroScan dalam mendiagnosis fibrosis-sirosis kronik. Data dianalisis dengan menggunakan SPSS 20.
Hasil: APRI terhadap METAVIR mendiagnosis fibrosis berat dan sirosis dengan sensitivitas 40%, spesifitas 
83,9%, nilai prediktif positif (NPP) 61,5%, nilai prediktif negatif (NPN) 68,4%, likelihood ratio (LR) positif 2,48 
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dan LR negatif 0,72 dengan akurasi diagnostik 66,7%. Nilai AUROC 0,619 (95% CI = 0,457–0,782); p > 0,05; 
kappa = 0,255; p > 0,05. Nilai prediktif FibroScan terhadap METAVIR dalam diagnosis fibrosis berat dan sirosis 
dengan sensitivitas 75% dan spesifitas 67,6% adalah NPP 60%, NPN 67,7%, LR positif 2,31 dan LR negatif 
0,36 dengan akurasi diagnostik 70,6%. Nilai AUROC 0,714 (95% CI = 0,567–0,861); kappa = 0,409; p < 0,05.
Simpulan: Akurasi FibroScan lebih baik dibandingkan dengan APRI dalam memprediksi fibrosis berat - 
sirosis pada pasien dengan penyakit hepatitis B kronik.
Kata kunci: APRI, FibroScan, biopsi hati, hepatitis B kronik
INTRODUCTION 
Early detection of liver fibrosis is essential as a 
leading point to direct further treatment for patients with 
chronic viral hepatitis. In those patients, examinations 
to determine the degree of severity for liver fibrosis 
have been recommended by the American Association 
for Study of Liver Disease (AASLD) and European 
Association for Study of Liver (EASL) in order to 
recognize those who are at risk for developing chronic 
liver disease as well as their anti-viral treatment.1-3
Liver biopsy is still the gold standard procedure to 
determine the degree of severity for liver fibrosis in 
spite of its limitations that have been reported since 
it is an invasive procedure which may have sampling 
error, inter- and intra-observer variation and may cause 
inconvenience for the patients when the procedure 
should be repeated. As there are many limitations of 
biopsy procedure, alternative non-invasive procedures 
are explored in order to determine the accurate and 
acceptable diagnosis of liver fibrosis. Some simple 
serum markers have widely reported as the substitutes 
for assessing liver fibrosis, i.e. aspartate transaminase 
to alanine transaminase ratio (AAR), aspartate 
aminotransferase to platelet ratio index (APRI), age 
platelet count index (API) and many other markers. 
Among all of the markers, APRI has been extensively 
used since it is simple and inexpensive.4-8
Recently, the measurement of liver stiffness 
using transient elastrography such as FibroScan has 
been proven in many studies as an accurate tool 
for predicting liver fibrosis in patients with chronic 
hepatitis C. The studies mainly are European studies 
since the incidence of chronic hepatitis C is relatively 
high there, but the number of studies on chronic 
hepatitis B is still limited; while only a few of studies 
indicate that the assessment using FibroScan has the 
same quality in predicting liver fibrosis with various 
etiologies in patients with chronic hepatitis. However, 
a validation of varied cut off point on some groups 
of chronic liver disease with different etiologies is 
necessary before a valid recommendation is issued by 
FibroScan work out in daily practice.9-13 Therefore, the 
aim of the present study was to evaluate the accuracy 
of FibroScan to diagnose chronic hepatitis B and to 
compare it with APRI by using liver biopsy as the gold 
standard procedure. 
METHOD
A cross sectional study was conducted in 51 
patients at the Division of Gastroentero-hepatology, 
Department of Internal Medicine, Adam Malik 
Hospital, Medan between April 2011 and July 2013. 
The inclusion criteria were patients with chronic 
hepatitis B, persistent positive hepatitis B surface 
antigen (HBsAg) results for at least 6 months and 
elevated alanine transaminase (ALT) serum above 
normal limit for at least twice in the last 6 months, HBV 
DNA > 2,000 IU/mL, both male and female patients 
aged > 18 years and were willing to participate in the 
study. The exclusion criteria included patients with 
decompensated liver cirrhosis who were confirmed 
by clinical examination, laboratory work out and 
ultrasonography (USG), patients who consumed 
alcohol > 30 g/day, patients with metabolic liver 
disease, neoplasm, chronic liver infection other than 
chronic hepatitis B, patients with cholestatic liver 
disease, autoimmune hepatitis and patients with HIV/
AIDS. The patients underwent FibroScan examination 
of their right liver lobe and assessed through intercostal 
plane. The stadium of liver fibrosis is determined based 
on a defined system on a scale of F0-F4 in FibroScan. 
In order to calculate APRI score a serial of 
examinations was done including laboratory workout 
for amino transaminase (AST), ALT, platelet counts and 
USG guided liver biopsy. The biopsy was performed 
based on METAVIR score. Specimens of liver tissue 
were examined with 1.4-2 cm length and minimal of 
8-10 portal triads. Hematoxillin eosin staining of the 
liver tissues was also performed without including 
the data of patients. Liver biopsy was performed in 7 
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days following the laboratory workout and FibroScan. 
The formula to calculate the score was:
APRI = AST level (U/L) / upper normal limit of AST (U/L)  x 100
Thrombocyte (109/L)
The cut-off point of APRI was ≤ 1.50 for mild 
to severe fibrosis and > 1.50 for severe fibrosis 
to cirrhosis.8 The cut-off point for FibroScan was 
determined according to Ledingen, i.e. F0-2 ≤ 9.3 kPa 
= mild to moderate fibrosis; F3-4 > 9.3 kPa = severe 
fibrosis to cirrhosis.14 For METAVIR score, F0 = no 
fibrosis; F1 = fibrosis are confined to enlarged portal 
tract; F2 = the development of periportal septa or 
portal septa with intact architecture; F3 = fibrosis with 
architectural distortion (fibrosis septa bridging) but no 
obvious cirrhosis; F4 = probable or definite cirrhosis.15
In order to determine the diagnostic value of APRI 
and FibroScan, an evaluation was conducted based on 
the analysis on receiver operating characteristic (ROC) 
curve and assessing the sensitivity (Se), specificity 
(Sp), positive predictive value (PPV), negative 
predictive value (NPV), diagnostic accuracy (DA), 
positive likelihood ratio (LR+) and negative likelihood 
ratio (LR-), which were calculated based on the cut-
off points as mentioned in the original publication. 
Statistical analysis was performed using SPSS 20.0. 
The present study was approved by the Research 
Ethics Committee, Faculty of Medicine, University 
of Sumatera Utara.
RESULTS
Table 1. Baseline data of the patients
Variable Hepatitis Bn (%)
Patients (n) 51
Sex
Male
Female
29 (56.9%)
22 (43.1%)
Age (years) 43.5 (SD ± 11.50)* 
AST (U/L) 38 (16 - 846)**
ALT (U/L) 62 (10 - 222)**
Thrombocyte (109/L) 160 (53 - 421)**
FibroScan (kPa) 4.90 (4.1 - 75)**
APRI score 0.58 (0.17 - 7.49)**
≤ 1.50 38 (74.5%)
> 1.50 13 (25.5%)
FibroScan (kPa) -
≤ 9.3 26 (51%)
> 9.3 25 (49%)
METAVIR-stage -
F0 – 2 31 (60.8%)
F3 – 4 20 (39.2%)
*mean, SD; **median, min-max; AST: aspartate transaminase; ALT: alanin 
transaminase; APRI: aspartate aminotransferase to platelet ratio index
Diagnostic Accuracy of APRI versus METAVIR
Table 2. The predictive value of APRI versus METAVIR for 
diagnosing severe fibrosis and cirrhosis 
Model Cut off
METAVIR
Se
(%) Sp PPV NPV
LR
AccF3 - 4
n = 20
F0 - 2
n = 31 + -
APRI > 1.50
n = 13
8 5 40 83.9 61.5 68.4 2.48 0.72 66.7
≤ 1.50
n = 38
12 26
APRI = aspartate aminotransferase to platelet ratio index; Se = sensitivity; Sp = 
specificity, PPV = positive predictive value; NPV = negative predictive value; LR = 
likelihood ratio; Acc = accuracy
On Table 2, out of 20 patients with severe fibrosis 
and cirrhosis based on METAVIR, there were 8 (40%) 
patients with APRI score > 1.50. The predictive value 
of APRI versus METAVIR for diagnosing severe 
fibrosis and cirrhosis with sensitivity 40%, specificity 
83.9% were PPV 61.5%, NPV 68.4% LR positive 2.48, 
LR negative 0.72 with diagnostic accuracy 66.7%, 
kappa 0.255; p > 0.05. The area value of under receiver 
operating curve (AUROC) in predicting severe fibrosis 
and cirrhosis for APRI was 0.619 (95% CI = 0.457 – 
0.782) with p > 0.05 (not significant) (Figure 1).
Figure 1. ROC curve of APRI versus METAVIR for predicting 
severe fibrosis and cirrhosis 
Diagnostic Accuracy of FibroScan versus METAVIR 
Table 3.The predictive value of FibroScan versus METAVIR for 
diagnosing severe fibrosis and cirrhosis 
Model Cut off
METAVIR
Se
(%)
Sp
(%)
PPV
(%)
NPV
(%)
LR Acc
(%)F3 - 4
n = 20
F0 - 2
n = 31 + -
Fibro 
Scan
> 9.3
n = 25
15 10 75 67.6 60 67.7 2.31 0.36 70.6
≤ 9.3
n = 26
5 21
Se: sensitivity; Sp: specificity, PPV: positive predictive value, NPV: negative predictive 
value, LR; likelihood ratio; Acc = accuracy
AUROC = 0.619p = 0.153
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Table 3 shows that of 20 patients with severe 
fibrosis and cirrhosis based on METAVIR, there were 
15 (75%) patients with the FibroScan value > 9.3 kPa. 
The predictive value of FibroScan on METAVIR for 
diagnosing severe fibrosis and cirrhosis with sensitivity 
75% and specificity 67.6% were PPV 60%, NPV 67.7% 
LR positive 2.31, and LR negative 0.36 with diagnostic 
accuracy 70.6%, kappa 0.409, p < 0.05. The AUROC 
value in predicting severe fibrosis and cirrhosis for 
FibroScan was 0.714 (95% CI = 0.457–0.782) with p 
< 0.05 (significant) (Figure 2).
Figure 2. ROC curve of FibroScan and METAVIR for predicting 
severe fibrosis and cirrhosis
Table 4. AUROC result and accuracy of fibrosis models for 
predicting severe fibrosis and liver cirrhosis 
Model AUROC 95% CI p Kappa Acc(%)
APRI – 
METAVIR
0.619 0.457 – 0.782 0.153 0.255 66.7
FibroScan - 
METAVIR
0.714 0.567 – 0.861 0.001 0.409 70.6
Acc: accuracy; CI: confidence interval
40%, Sp 83.9%, PPV 61.5%, NPV 68.4%, LR positive 
2.48, LR negative 0.36, and AUROC value 0.72 
(95% CI = 0.457–0.782) with accuracy 66.7%. The 
NPV value for predicting severe fibrosis and cirrhosis 
was higher than PPV and a low value of positive LR 
was also found. The correlation between APRI and 
METAVIR was weak and insignificant (kappa 0.255; 
p > 0.05).
Bonnard et al who conducted a study in 50 patients 
with chronic hepatitis B and using a cut-off point 1.2 
found Se 50%, Sp 51%, PPV 23%, NPV 75%, and 
AUROC value 0.50.17 Some studies showed that with 
a cut-off point more than 1.50, the AUROC value was 
> 0.70, which means that APRI has moderate accuracy 
in predicting the degree of severe liver fibrosis and 
cirrhosis. Jin et al from China evaluated 9 studies 
in their meta-analysis (n = 1,798) on the diagnostic 
accuracy of APRI in patients with chronic hepatitis B 
and showed that the significant prevalence for fibrosis 
was 53.1% and for cirrhosis was 13.5%. When the cut-
off point for APRI was 1.5, they found Se 49% and Sp 
84%. Cirrhosis was determined when the cut-off for 
APRI was 1.0–1.5 with Se 54% and Sp 87%. When the 
cut-off point for APRI was 2.0, they found Se 28% and 
Sp 87%. The meta-analysis concluded that the value 
of APRI for significant identification of fibrosis and 
cirrhosis in patients with chronic hepatitis B was low.18
Some researchers conclude that APRI is not 
accurate in predicting significant fibrosis and cirrhosis 
in patients with chronic hepatitis B with varied 
AUROC value, PPV and NPV. Wai et al were the 
first who reported APRI for patients with chronic 
hepatitis B and showed that the AUROC value of 
APRI for predicting significant fibrosis and cirrhosis 
were 0.673 and 0.626. They concluded that in their 
study APRI was not accurate for predicting significant 
fibrosis and cirrhosis.19 Furthermore, Sebastiani et 
al also showed that the AUROC value of APRI for 
predicting significant fibrosis and cirrhosis were 0.72 
and 0.64. The NPV was higher than PPV for predicting 
cirrhosis.20 The predictive value of FibroScan in the 
present study with cut-off point > 9.4 kPa versus 
METAVIR for diagnosis of severe fibrosis and cirrhosis 
were Se 75%, Sp 67.6%, PPV 60%, NPV 67.7%, LR 
positive 2.31 and LR negative 0.36 with diagnostic 
accuracy 70.6%. Diagnostic performance of FibroScan 
was then evaluated by assessing the AUROC value 
for predicting severe liver fibrosis and cirrhosis. The 
AUROC value for FibroScan was 0.714 (95% CI = 
0.567–0.861) with p < 0.05 (kappa 0.409; p < 0.05). 
Similar study was also conducted by Sporea et al who 
AUROC = 0.714p = < 0.05
DISCUSSION
APRI scoring system is a relatively inexpensive 
method and easily performed by clinicians. Many 
researchers have evaluated the degree of liver fibrosis 
based on APRI in patients with chronic hepatitis C.7 
However, there are only a few of publications for 
patients with chronic hepatitis B with different values 
of the cut-off points. A study conducted by Amorin et 
al in 119 patients with chronic hepatitis B with cut-off 
point > 1.50 found Se 42%, Sp 94%, PPV 77%, NPV 
75%, and AUROC value 0.79 with accuracy 76%.16 
Similar results have also been found in the present 
study, i.e. with APRI cut-off point > 1.50, we found Se 
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studied 140 patients with chronic hepatitis B and 317 
patients with chronic hepatitis. An evaluation of severe 
fibrosis was performed for both groups.21 
Mean value of liver stiffness for chronic hepatitis B 
was the same with chronic hepatitis C, i.e. F1 = 6.5 ± 
1.9 kPa vs. 5.8 ± 2.1 kPa (p = 0.0889); F2 = 7.1 ± 2 kPa 
vs. 6.9 ± 2.5 kPa (p = 0.3369); F3 = 9.1 ± 3.6 kPa vs. 9.9 
± 5 kPa (p = 0.7038); F4 = 19.8 ± 8.6 kPa vs. 17.3 ± 6.1 
kPa (p = 0.6574). There was a significant correlation 
of FibroScan versus METAVIR between those with 
chronic hepatitis C and B (Spearman r = 0.578; p < 
0.0001; r = 0.408, p < 0.0001). AUROC value for 
severe fibrosis in chronic hepatitis B with cut-off point 
of 8.8 kPa was 0.753; Se 53% with Sp 85%, PPV 86% 
and NPV 82%. While for chronic hepatitis C with cut-
off point 8.6 kPa the AUROC value was 0.797 with 
Se 62%, Sp 81%, PPV 71%, NPV 75% and when the 
values for hepatitis B and C were combined with cut-
off point of 8.7, the AUROC value was 0.786 with Se 
60%, Sp 83%, PPV 68%, NPV 77%. They concluded 
that there was no statistical difference regarding on 
the mean value of liver stiffness between those with 
chronic hepatitis B and C with an equal degree of liver 
fibrosis.21  Vigano et al who studied 217 patients with 
chronic hepatitis B with cut-off point for FibroScan of 
8.7 kPa in predicting severe fibrosis found Se 64%, Sp 
92%; while in predicting cirrhosis with cut-off point 
of 9.4 kPa, they found Se 100% and Sp 82%.22  The 
main difference of all the above-mentioned studies is 
the use of different and undetermined cut-off point 
for examination based on FibroScan. In which Ziol et 
al studied patients with chronic hepatitis B and they 
conclude that FibroScan can be included in a category 
with level of evidence of 2B.10
APRI was firstly introduced by Wai et al for 
predicting liver fibrosis in chronic hepatitis C with 
AUROC value of 0.80 (95% CI = 0.74–0.87).8 The 
comparison of diagnostic accuracy of FibroScan 
versus APRI for identifying the degree of severe liver 
fibrosis and cirrhosis was performed since APRI could 
be easily calculated from the results of routine blood 
test in patients with chronic viral hepatitis. Moreover, 
they also evaluated how APRI in patients with chronic 
hepatitis B has important role as the non-invasive 
method as well as a follow-up tool following the 
treatment. APRI can be performed for all patients; 
while FibroScan cannot be done for certain patients, 
particularly for patients with obesity and a narrow 
intercostal space as the transducer cannot be placed 
on the skin. 
In the present study, FibroScan is more superior 
to APRI for diagnosis of severe liver fibrosis and 
cirrhosis with higher values of AUROC, sensitivity 
and specificity, as well as higher degree of accuracy. 
The measurement of liver stiffness by FibroScan would 
assess the liver tissue with diameter of 1 cm2 and 4 cm 
length. The volume of this tissue is 100x greater than the 
tissues obtained for liver biopsy with fast examination 
(< 5 minutes) and easily performed for patients treated 
at the outpatient clinic. Moreover, the results are rapidly 
obtained with an independent operator.23
The drawbacks of the present study are: (1) The 
readings of liver tissue was not confirmed by other 
pathologist, which according to the literature, there 
can be 20% intra- and inter-observer differences for 
evaluation of staging.6 Likewise, for FibroScan, there 
is 2% of intra- and inter-observer differences;24 (2) 
The length of liver biopsy tissue may also have role 
in the interpretation of liver fibrosis. The mean length 
of liver tissue specimens in the present study is 15 
mm; while the length suggested by Bedossa et al is 25 
mm;25 (3) The cut-off point was estimated from other 
investigator; (4) Small sample size.
CONCLUSION
The present study indicates that FibroScan is more 
accurate than APRI for evaluating the degree of severe 
fibrosis and cirrhosis in liver biopsy of patients with 
chronic hepatitis B. The APRI examination is more 
simple and cheaper for evaluating the degree of liver 
fibrosis. 
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